
“A founding principle of the Bristol-Myers Squibb - Pfizer Alliance is built around the belief that a patient’s first clinical indication and knowledge of AFib should never be a stroke.” – Gail Wygant, Director of Worldwide Health Economics and Outcomes Research at Bristol-Myers Squibb
Additionally, among patients who experience a stroke, those with AFib incur higher costs relative to those without AFib, largely due to longer inpatient stays as well as increased probability of a second stroke. Helping spread awareness of AFib remains a resounding mission for stakeholders across the continuum of care.
Each day, the BMS-Pfizer Alliance works to support ongoing research and implement ways to better help patients so that there is a future where stroke is not the first sign of AFib.